Salute e Benessere
Half-year report
DXS INTERNATIONAL PLC
(AQSE: DXSP)
HALF YEAR RESULTS
DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to provide shareholders with its unaudited interim results for the half year ending 31 October 2024.
Financial highlights:
Operational highlights:
Outlook
Current lack of available NHS budgets remains a barrier to closing new sales. Armed with evidence of the effectiveness of our solutions in solving real problems for both the patient and the taxpayer, we continue to the believe that it is a matter of time before new NHS funding specifically aimed at alleviating NHS pressures by the introduction of innovative digital solutions becomes more readily available.
In addition, we continue our policy of:
David Immelman, Chief Executive of DXS, commented:
“Although gaining sales growth remains frustratingly slow, I repeat my statement from a year ago: We remain confident that we have exceptionally effective solutions for helping the NHS to resolve their acknowledged problems and that this can be demonstrated by provable data which saves millions of pounds annually, saves patient lives, helps with the resource shortage and contribute to the NHS Net Zero Targets.”
“Our team remains fuelled with conviction and enthusiasm for what we have to offer to the NHS and beyond. The Board continues with salary cost cuts as a contribution to cash flow.”
The Directors of DXS International plc accept responsibility for this announcement. This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).
INTERIM RESULTS to 31 OCTOBER 2024
Consolidated Income Statement
for the six months ended 31 October 2024
Consolidated Statement of other Comprehensive Income
for the six months ended 31 October 2024
STATEMENT of FINANCIAL POSITION
as at 31 October 2024
Statement Of Cash Flows
Six months ended 31 October 2024
Net Debt Reconciliation
The above figures have not been reviewed by the company's auditors Crowe U.K. LLP.
The Directors of DXS International plc accept responsibility for this announcement
Contacts:
Notes to Editors
About DXS:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti